Stati Uniti - inglese - NLM (National Library of Medicine)

b. braun medical inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 5% dextrose injection usp is indicated for use in adults and pediatric patients as sources of calories and water for hydration. this product is designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. consult prescribing information for indications and usage of drug additives to be administered in this manner. solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products. do not administer 5% dextrose injection usp simultaneously with blood through the same infusion set because hemolysis or pseudoagglutination may occur.

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escheric

Stati Uniti - inglese - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol tablet is indicated for: -   the management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) -   the management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels -   the management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables) limitations of use allopurinol tablets are not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets are contraindicated in patients with a history of hypersensitivity reaction to allopurinol or to any of the ingredients of allopurinol

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - atorvastatin calcium trihydrate (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: in adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: in adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: atorvastatin calcium tablets are indicated: atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (fredrickson types i and v). risk summary atorvastatin calcium is contraindicated for use in pregnant women since safety in pregnant women has not been established and there is no apparent benefit of lipid lowering drugs during pregnancy. because hmg-coa reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, atorvastatin calcium tablets may cause fetal harm when administered to a pregnant woman. atorvastatin calcium tablets should be discontinued as soon as pregnancy is recognized [see contraindications (4)] . limited published data on the use of atorvastatin are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage. in animal reproduction studies in rats and rabbits there was no evidence of embryo-fetal toxicity or congenital malformations at doses up to 30 and 20 times, respectively, the human exposure at the maximum recommended human dose (mrhd) of 80 mg, based on body surface area (mg/m2 ). in rats administered atorvastatin during gestation and lactation, decreased postnatal growth and development was observed at doses ≥ 6 times the mrhd (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data human data limited published data on atorvastatin calcium from observational studies, meta-analyses and case reports have not shown an increased risk of major congenital malformations or miscarriage. rare reports of congenital anomalies have been received following intrauterine exposure to other hmg-coa reductase inhibitors. in a review of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed what would be expected in the general population. the number of cases is adequate to exclude a ≥ 3 to 4-fold increase in congenital anomalies over the background incidence. in 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. animal data atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma. atorvastatin was administered to pregnant rats and rabbits during organogenesis at oral doses up to 300 mg/kg/day and 100 mg/kg/day, respectively. atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. these doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure at the mrhd based on surface area (mg/m2 ). in rats, the maternally toxic dose of 300 mg/kg resulted in increased post-implantation loss and decreased fetal body weight. at the maternally toxic doses of 50 and 100 mg/kg/day in rabbits, there was increased post-implantation loss, and at 100 mg/kg/day fetal body weights were decreased. in a study in pregnant rats administered 20, 100, or 225 mg/kg/day from gestation day 7 through to lactation day 20 (weaning), there was decreased survival at birth, postnatal day 4, weaning, and post-weaning in pups of mothers dosed with 225 mg/kg/day, a dose at which maternal toxicity was observed. pup body weight was decreased through postnatal day 21 at 100 mg/kg/day, and through postnatal day 91 at 225 mg/kg/day. pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae detachment and eye-opening at 225 mg/kg/day). these doses correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human exposure at the mrhd, based on auc. risk summary atorvastatin calcium use is contraindicated during breastfeeding [see contraindications (4)] . there is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. it is not known whether atorvastatin is present in human milk, but it has been shown that another drug in this class passes into human milk and atorvastatin is present in rat milk. because of the potential for serious adverse reactions in a breastfed infant, advise women that breastfeeding is not recommended during treatment with atorvastatin calcium. contraception atorvastatin calcium may cause fetal harm when administered to a pregnant woman. advise females of reproductive potential to use effective contraception during treatment with atorvastatin calcium [see use in specific populations (8.1)] . heterozygous familial hypercholesterolemia (hefh) the safety and effectiveness of atorvastatin calcium have been established in pediatric patients, 10 years to 17 years of age, with hefh as an adjunct to diet to reduce total cholesterol, ldl-c, and apo b levels when, after an adequate trial of diet therapy, the following are present: use of atorvastatin calcium for this indication is supported by evidence from [see dosage and administration (2.2), adverse reactions (6.1), clinical pharmacology (12.3), and clinical studies (14.6)] : advise postmenarchal girls of contraception recommendations, if appropriate for the patient [see use in specific populations (8.1), (8.3)] . the long-term efficacy of atorvastatin calcium therapy initiated in childhood to reduce morbidity and mortality in adulthood has not been established. the safety and efficacy of atorvastatin calcium have not been established in pediatric patients younger than 10 years of age with hefh. homozygous familial hypercholesterolemia (hofh) clinical efficacy of atorvastatin calcium with dosages up to 80 mg/day for 1 year was evaluated in an uncontrolled study of patients with hofh including 8 pediatric patients [see clinical studies (14.5)]. of the 39,828 patients who received atorvastatin calcium in clinical studies, 15,813 (40%) were ≥ 65 years old and 2,800 (7%) were ≥ 75 years old. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. since advanced age (≥ 65 years) is a predisposing factor for myopathy, atorvastatin calcium should be prescribed with caution in the elderly. atorvastatin calcium is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [see contraindications (4) and clinical pharmacology (12.3)].

Stati Uniti - inglese - NLM (National Library of Medicine)

stearns packaging corporation - iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4) - first aid: eyes: if contact with eyes occurs, flush with plenty of cool water for 15 minutes. consult a physician. internal: may be harmful if swallowed. if ingested, drink large amounts of water. do not induce vomiting. drink large quantities of water. see physician immediately. get medical attention immediately. 24 hour emergency contact 1-800-255-3924

Stati Uniti - inglese - NLM (National Library of Medicine)

charm-tex, inc. usa. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - - helps protect against cavities.

Stati Uniti - inglese - NLM (National Library of Medicine)

harris teeter - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - pain reliever/fever reducer - temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis - headache - toothache - backache - menstrual cramps - the common cold - muscular aches - minor pain of arthritis - temporarily reduces fever

Stati Uniti - inglese - NLM (National Library of Medicine)

farouk systems, inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - use for hand-washing to decrease bacteria on the skin, only when water is not available. directions wet hands thoroughly with product and allow to dry without wiping for children under 6, use only under adult supervision use for hand-washing to decrease bacteria on the skin, only when water is not available.

Stati Uniti - inglese - NLM (National Library of Medicine)

walgreens - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - arthritis pain reliever - for the temporary relief of arthritis pain only in the following areas: head, wrist, elbow (upper body areas) ■ foot, ankle, knee (lower body areas) - head, wrist, elbow (upper body areas) ■ foot, ankle, knee (lower body areas) - this product may take up to 7 days to work for arthritis pain; it is not for immediate relief. if no pain relief in 7 days, stop use

Stati Uniti - inglese - NLM (National Library of Medicine)

yiling pharmaceutical,inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - 1.1 acute coronary syndrome (acs) - clopidogrel is indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel should be administered in conjunction with aspirin. - clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopdiogrel should be administered in conjunction with aspirin. 1.2 recent mi, recent stroke, or established peripheral arterial disease in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopdigorel is indicated to reduce the rate of mi and stroke. 4.1 active bleeding clopidogrel is contraindicated in patients with active pathological bleeding